Study design
IMMUNOCITRE was a double-blind randomized placebo-controlled trial involving four intensive care units (ICUs) in France. The study protocol was approved by an independent ethics committee (Because flow cytometry analysis for immune monitoring required live cell samples, patients were included only from Monday to Wednesday so that each sample (day 1, day 3, and day 7) fell on a regular workday.